RENERVE NEWSLETTER December 2021

ReNerve has made considerable progress over the past twelve months. ReNerve is well capitalised, optimistic that they will be able to secure FDA marketing approval for the NervAlign™ Nerve Cuff in early 2022 and generate first sales and looking forward to progressing their broader product portfolio.